H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine D-index 134 Citations 87,277 987 World Ranking 859 National Ranking 519

Research.com Recognitions

Awards & Achievements

2007 - Fellow of the American Association for the Advancement of Science (AAAS)

Member of the Association of American Physicians

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Gene

John C. Byrd spends much of his time researching Chronic lymphocytic leukemia, Internal medicine, Immunology, Leukemia and Cancer research. Ibrutinib is the focus of his Chronic lymphocytic leukemia research. His studies deal with areas such as Venetoclax, breakpoint cluster region, Neutropenia and Bruton's tyrosine kinase as well as Ibrutinib.

His studies deal with areas such as Gastroenterology, Surgery and Oncology as well as Internal medicine. His Leukemia research is multidisciplinary, incorporating perspectives in Cancer, Chemotherapy, Monoclonal, Myeloid and Myeloid leukemia. The Cancer research study combines topics in areas such as DNA methylation, Apoptosis, Molecular biology, Signal transduction and Kinase.

His most cited work include:

  • Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling (8095 citations)
  • Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study (1802 citations)
  • Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia (1539 citations)

What are the main themes of his work throughout his whole career to date?

John C. Byrd focuses on Chronic lymphocytic leukemia, Internal medicine, Cancer research, Immunology and Oncology. His Chronic lymphocytic leukemia study is focused on Leukemia in general. In his work, Decitabine is strongly intertwined with Myeloid leukemia, which is a subfield of Leukemia.

His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Surgery. His Cancer research research includes themes of Apoptosis, B cell, Cytotoxicity, Kinase and In vivo. John C. Byrd interconnects Clinical trial, Chemotherapy, Phases of clinical research and Chemoimmunotherapy in the investigation of issues within Oncology.

He most often published in these fields:

  • Chronic lymphocytic leukemia (44.13%)
  • Internal medicine (41.68%)
  • Cancer research (28.94%)

What were the highlights of his more recent work (between 2017-2021)?

  • Internal medicine (41.68%)
  • Chronic lymphocytic leukemia (44.13%)
  • Oncology (23.97%)

In recent papers he was focusing on the following fields of study:

His primary areas of investigation include Internal medicine, Chronic lymphocytic leukemia, Oncology, Cancer research and Ibrutinib. His work on Leukemia, Rituximab, Cancer and Venetoclax as part of general Internal medicine study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. His Chronic lymphocytic leukemia research incorporates themes from Relapsed refractory, B cell and Phases of clinical research.

His Oncology research is multidisciplinary, incorporating elements of Clinical trial, Refractory, Chemotherapy and NPM1. John C. Byrd combines subjects such as Cell culture, Bruton's tyrosine kinase, In vivo and Cytotoxicity with his study of Cancer research. His Ibrutinib study also includes

  • Adverse effect that intertwine with fields like Progressive disease,
  • Discontinuation, which have a strong connection to Gastroenterology and Neutropenia.

Between 2017 and 2021, his most popular works were:

  • iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL (392 citations)
  • Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL (289 citations)
  • Single-Agent Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia: A 5-Year Experience (201 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Gene

His primary scientific interests are in Internal medicine, Chronic lymphocytic leukemia, Ibrutinib, Leukemia and Oncology. As part of one scientific family, John C. Byrd deals mainly with the area of Internal medicine, narrowing it down to issues related to the Gastroenterology, and often Progressive disease. His studies in Chronic lymphocytic leukemia integrate themes in fields like Cancer research, Neutropenia and Bruton's tyrosine kinase.

His study on Ibrutinib also encompasses disciplines like

  • Ofatumumab which connect with Fludarabine,
  • Venetoclax together with Phases of clinical research, Obinutuzumab and Minimal residual disease,
  • [email protected] and related Chemotherapy. His research in Leukemia intersects with topics in Cancer, Clinical trial, Survival rate, Hematology and Myeloid leukemia. His Oncology research includes elements of Refractory Chronic Lymphocytic Leukemia and Monoclonal.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Ash A. Alizadeh;Michael B. Eisen;R. Eric Davis;Izidore S. Lossos.
Nature (2000)

10864 Citations

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux;Ghulam J. Mufti;Eva Hellstrom-Lindberg;Valeria Santini.
Lancet Oncology (2009)

2415 Citations

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

John C. Byrd;Krzysztof Mrózek;Richard K. Dodge;Andrew J. Carroll.
Blood (2002)

2169 Citations

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

John C. Byrd;Richard R. Furman;Steven E. Coutre;Ian W. Flinn.
The New England Journal of Medicine (2013)

2148 Citations

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

J. C. Byrd;J. R. Brown;Susan O'Brien;J. C. Barrientos.
The New England Journal of Medicine (2014)

1470 Citations

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

Andreas Rosenwald;Ash A. Alizadeh;George Widhopf;Richard Simon.
Journal of Experimental Medicine (2001)

1348 Citations

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Michael J. Keating;Ian Flinn;Vinay Jain;Jacques-Louis Binet.
Blood (2002)

1190 Citations

ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia

Laura Z. Rassenti;Lang Huynh;Tracy L. Toy;Liguang Chen.
The New England Journal of Medicine (2004)

1131 Citations

MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.

Ramiro Garzon;Shujun Liu;Muller Fabbri;Zhongfa Liu.
Blood (2009)

960 Citations

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

Jennifer A. Woyach;Richard R. Furman;Ta Ming Liu;Hatice Gulcin Ozer.
The New England Journal of Medicine (2014)

921 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing John C. Byrd

Hagop M. Kantarjian

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center

Publications: 252

Susan O'Brien

Susan O'Brien

University of California, Irvine

Publications: 230

Michael Hallek

Michael Hallek

University of Cologne

Publications: 224

Michael J. Keating

Michael J. Keating

The University of Texas MD Anderson Cancer Center

Publications: 222

William G. Wierda

William G. Wierda

The University of Texas MD Anderson Cancer Center

Publications: 207

Stephan Stilgenbauer

Stephan Stilgenbauer

University of Ulm

Publications: 187

Jennifer R. Brown

Jennifer R. Brown

Harvard University

Publications: 158

Guillermo Garcia-Manero

Guillermo Garcia-Manero

The University of Texas MD Anderson Cancer Center

Publications: 158

Hartmut Döhner

Hartmut Döhner

University of Ulm

Publications: 154

Thomas J. Kipps

Thomas J. Kipps

University of California, San Diego

Publications: 149

Louis M. Staudt

Louis M. Staudt

National Institutes of Health

Publications: 147

Randy D. Gascoyne

Randy D. Gascoyne

BC Cancer Agency

Publications: 146

Gianluca Gaidano

Gianluca Gaidano

University of Eastern Piedmont Amadeo Avogadro

Publications: 142

Jorge E. Cortes

Jorge E. Cortes

Augusta University

Publications: 142

Alessandra Ferrajoli

Alessandra Ferrajoli

The University of Texas MD Anderson Cancer Center

Publications: 138

Jan A. Burger

Jan A. Burger

The University of Texas MD Anderson Cancer Center

Publications: 137

Something went wrong. Please try again later.